Skip to main content
SpringerLink
Log in

NSCLC in the Elderly—The Legacy of Therapeutic Neglect

  • Geriatric Oncology
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Although the majority of patients diagnosed with non-small cell lung cancer (NSCLC) are elderly, most clinical trials available to guide care either exclude the elderly or underrepresent them. This disregard for the elderly lung cancer patient extends to the clinical realm, where the elderly with lung cancer are less likely to be treated with either curative, or life-extending, palliative therapy. Few elderly-specific phase III trials are available to provide level I evidence. However, subgroup analyses and meta-analyses of large clinical trials enrolling substantial numbers of elderly patients are available to guide care, although these are potentially subject to selection bias. These trials suggest that the fit elderly derive as much benefit from surgery, chemoradiation, and platinum-based doublet chemotherapy as younger patients across all stages of disease. For the less fit elderly, in particular those with limited performance status or significant co-morbidities, less aggressive regimens are likely preferred, with the goal of extending life and delaying or suppressing cancer symptoms. Ultimately, care decisions must incorporate knowledge of the literature, evaluation of the patient’s clinical characteristics, and patient priorities. The elderly should be aggressively recruited to clinical trials, including elderly-specific trials and trials of patients with limited performance status and co-morbidities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ries LAG, Melbert D, Krapcho M, et al., eds: SEER Cancer Statistics Review, 1975–2005, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008

  2. Owonikoko TK, Ragin CC, Belani CP: Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol, 2007. 25(35): p. 5570-7. doi:10.1200/JCO.2007.12.5435

    Article  PubMed  Google Scholar 

  3. Vercelli M, Capocaccia R, Quaglia A, Casella C, Puppo A, Coebergh JW. Relative survival in elderly European cancer patients: evidence for health care inequalities The EUROCARE Working Group. Crit Rev Oncol Hematol, 2000. 35(3): p. 161-79. doi:10.1016/S1040-8428(00)00075-5

    Article  CAS  PubMed  Google Scholar 

  4. Kates MR, Perez X, Gribetz J, Swanson SJ, McGinn T, Wisnivesky JP: Validation of a Model to Predict Perioperative Mortality from Lung Cancer Resection in the Elderly. Am J Respir Crit Care Med, 2008.

    Article  PubMed  Google Scholar 

  5. Janssen-Heijnen ML, Schipper RM, Razenberg PP, Crommelin MA, Coebergh JW: Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer, 1998. 21(2): p. 105-13. doi:10.1016/S0169-5002(98)00039-7

    Article  CAS  PubMed  Google Scholar 

  6. Wang J, Kuo YF, Freeman J, Markowitz AB, Goodwin JS: Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer. Cancer, 2008. 112(2): p. 382-90. doi:10.1002/cncr.23181

    Article  PubMed  Google Scholar 

  7. Firat S, Pleister A, Byhardt RW, Gore E: Age is independent of comorbidity influencing patient selection for combined modality therapy for treatment of stage III nonsmall cell lung cancer (NSCLC). Am J Clin Oncol, 2006. 29(3): p. 252-7. doi:10.1097/01.coc.0000217824.20290.ab

    Article  CAS  PubMed  Google Scholar 

  8. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst, 1999. 91(1): p. 66-72. doi:10.1093/jnci/91.1.66

    Article  Google Scholar 

  9. Scagliotti GV, Parikh P, von Pawel J: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008. 26(21): p. 3543-51. doi:10.1200/JCO.2007.15.0375

    Article  CAS  PubMed  Google Scholar 

  10. Sandler A, Gray R, Perry MC: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006. 355(24): p. 2542-50. doi:10.1056/NEJMoa061884

    Article  CAS  PubMed  Google Scholar 

  11. Pirker R, Szczesna A, von Pawel J, etal.: FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008, 26(May 20 Suppl):abstr 3

    Google Scholar 

  12. Lang K, Marciniak MD, Faries D: Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer, 2008.

    Google Scholar 

  13. Hutchins LF, U.J., Crowley JJ, etal., Underrepresentation of patients 65 years of age or older in cancer-treatmetn trials. N Engl J Med, 1999. 341: p. 2061-2067. doi:10.1056/NEJM199912303412706

    Article  CAS  PubMed  Google Scholar 

  14. Talarico, L., G. Chen, and R. Pazdur, Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol, 2004. 22(22): p. 4626-31. doi:10.1200/JCO.2004.02.175

    Article  PubMed  Google Scholar 

  15. Mountain, C.F., Revisions in the International System for Staging Lung Cancer. Chest, 1997. 111(6): p. 1710-7. doi:10.1378/chest.111.6.1710

    Article  CAS  PubMed  Google Scholar 

  16. Pignon JP, Tribodet H, Scagliotti GV: Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol, 2008. 26(21): p. 3552-9. doi:10.1200/JCO.2007.13.9030

    Article  PubMed  Google Scholar 

  17. Lichtman SM, Wildiers H, Chatelut E: International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients–an analysis of the medical literature. J Clin Oncol, 2007. 25(14): p. 1832-43. doi:10.1200/JCO.2007.10.6583

    Article  CAS  PubMed  Google Scholar 

  18. Read WL, Tierney RM, Page NC: Differential prognostic impact of comorbidity. J Clin Oncol, 2004. 22(15): p. 3099-103. doi:10.1200/JCO.2004.08.040

    Article  PubMed  Google Scholar 

  19. Tierney RM, Read WL, Page NC, Govindan R, Piccirillo JF: The differential prognostic impact of comorbidity in lung cancer. Proc Am Soc Clin Oncol 2002, 21:abstr 1008

    Google Scholar 

  20. Fruh M, Rolland E, Pignon JP: Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol, 2008. 26(21): p. 3573-81. doi:10.1200/JCO.2008.16.2727

    Article  CAS  PubMed  Google Scholar 

  21. Chemotherapy for non-small cell lung cancer. Non-small Cell Lung Cancer Collaborative Group. Cochrane Database Syst Rev 2000, 2000(2):CD002139

  22. Winton T, Livingston R, Johnson D: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med, 2005. 352(25): p. 2589-97. doi:10.1056/NEJMoa043623

    Article  CAS  PubMed  Google Scholar 

  23. Pepe C, Hasan B, Winton TL: Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol, 2007. 25(12): p. 1553-61. doi:10.1200/JCO.2006.09.5570

    Article  CAS  PubMed  Google Scholar 

  24. Pepe C, Hasan B, Winton T, etal., National Cancer Institute Of Canada Clinical Trials: Adjuvant chemotherapy in elderly patients: an analysis of National Cancer Institute of Canada Clinical Trials Group and Intergroup BR.10. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 2006, 24 (18S; June 20 Suppl):7009

  25. Dillman RO, Herndon J, Seagren SL, Eaton WL, Jr, Green MR: Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst, 1996. 88(17): p. 1210-5. doi:10.1093/jnci/88.17.1210

    Article  CAS  PubMed  Google Scholar 

  26. Sause W, Kolesar P, Taylor SI: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest, 2000. 117(2): p. 358-64. doi:10.1378/chest.117.2.358

    Article  CAS  PubMed  Google Scholar 

  27. Curran WJ, Scott CB, Langer CJ, etal.: Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG 9410. Proc Am Soc Clin Oncol 2003, 22:abstr 2499

  28. Jatoi A, Hillman S, Stella P: Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol, 2005. 23(36): p. 9113-9. doi:10.1200/JCO.2005.03.7465

    Article  PubMed  Google Scholar 

  29. Atagi S, Kawahara M, Tamura T: Standard thoracic radiotherapy with or without concurrent daily low-dose carboplatin in elderly patients with locally advanced non-small cell lung cancer: a phase III trial of the Japan Clinical Oncology Group (JCOG9812). Jpn J Clin Oncol, 2005. 35(4): p. 195-201. doi:10.1093/jjco/hyi060

    Article  PubMed  Google Scholar 

  30. Atagi S, Kawahara M, Ogawara M: Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Jpn J Clin Oncol, 2000. 30(2): p. 59-64. doi:10.1093/jjco/hyd022

    Article  CAS  PubMed  Google Scholar 

  31. www.clinicaltrials.gov. Cited January 5, 2008

  32. Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR: Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol, 1999. 17(1): p. 4-11.

    CAS  PubMed  Google Scholar 

  33. Rocha Lima CM, Herndon JE, 2nd, Kosty M, Clamon G, Green MR: Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer, 2002. 94(1): p. 181-7. doi:10.1002/cncr.10174

    Article  PubMed  Google Scholar 

  34. Schild SE, Stella PJ, Geyer SM: Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2002. 54(2): p. 370-8. doi:10.1016/S0360-3016(02)02930-9

    PubMed  Google Scholar 

  35. Schild SE, Stella PJ, Geyer SM: The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol, 2003. 21(17): p. 3201-6. doi:10.1200/JCO.2003.12.019

    Article  CAS  PubMed  Google Scholar 

  36. Albain KS, Crowley JJ, Turrisi AT, 3rd: Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol, 2002. 20(16): p. 3454-60. doi:10.1200/JCO.2002.03.055

    Article  CAS  PubMed  Google Scholar 

  37. Movsas B, Scott C, Sause W: The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys, 1999. 45(5): p. 1143-9. doi:10.1016/S0360-3016(99)00325-9

    Article  CAS  PubMed  Google Scholar 

  38. Langer CJ, Hsu C, Curran W, etal.: Do elderly patients (pts) with locally advanced non-small cell lung cancer (NSCLC) benefit from combined modality therapy? A secondary analysis of RTOG 94-10. Int J Radiat Oncol Biol Phys Volume 51, Issue 3, Supplement 1, 1 November 2001, Pages 20-21.

    Google Scholar 

  39. Schild SE, Mandrekar SJ, Jatoi A: The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer, 2007. 110(2): p. 363-8. doi:10.1002/cncr.22780

    Article  PubMed  Google Scholar 

  40. Albain KS, Swann RS, Rusch VR, etal.: Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005, 23(16S), Part I of II (June 1 Suppl):7014

  41. D’Angelillo M, Trodella L, Ramella S, etal.: Neoadjuvant chemoradiotherapy followed by surgery in elderly patients with locally advanced non-small cell lung cancer: analysis of feasibility, toxicity and factors predicting surgical resection and survival. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004, 22(14S; July 15 Suppl):7167

  42. Firat, S., R.W. Byhardt, and E. Gore, Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys, 2002. 54(2): p. 357-64. doi:10.1016/S0360-3016(02)02939-5

    PubMed  Google Scholar 

  43. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L: Comorbidity and functional status are independent in older cancer patients. J Clin Oncol, 1998. 16(4): p. 1582-7.

    CAS  PubMed  Google Scholar 

  44. Belani CP, Choy H, Bonomi P: Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol, 2005. 23(25): p. 5883-91. doi:10.1200/JCO.2005.55.405

    Article  CAS  PubMed  Google Scholar 

  45. Huber RM, Flentje M, Schmidt M: Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol, 2006. 24(27): p. 4397-404. doi:10.1200/JCO.2005.05.4163

    Article  CAS  PubMed  Google Scholar 

  46. Schaake-Koning C, van den Bogaert W, Dalesio O: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med, 1992. 326(8): p. 524-30.

    CAS  PubMed  Google Scholar 

  47. Blumenschein GR, Paulus R, Curran WJ, etal.: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): a report of the 2 year and median survival (MS) for the RTOG 0324 trial. J Clin Oncol 2008, 26(May 20 suppl):abstr 7516

    Google Scholar 

  48. Govindan R, Bogart J, Wang X, Liu D, Kratzke RA, Vokes EE: A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407—early evaluation of feasibility and toxicity. J Clin Oncol 2008, 26(May 20):abstr 7518

  49. Vrdoljak E, Mise K, Sapunar D, Rozga A, Marusic M: Survival analysis of untreated patients with non-small-cell lung cancer. Chest, 1994. 106(6): p. 1797-800. doi:10.1378/chest.106.6.1797

    Article  CAS  PubMed  Google Scholar 

  50. Gridelli C, Perrone F, Gallo C: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst, 2003. 95(5): p. 362-72.

    Article  CAS  PubMed  Google Scholar 

  51. Kudoh S, Takeda K, Nakagawa K: Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol, 2006. 24(22): p. 3657-63. doi:10.1200/JCO.2006.06.1044

    Article  CAS  PubMed  Google Scholar 

  52. Kawahara M., Furuse K, Segawa Y: Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer, 2001. 85(7): p. 939-43. doi:10.1038/sj.bjc.6692031

    Article  CAS  PubMed  Google Scholar 

  53. Hanna N, Shepherd FA, Fossella FV: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004. 22(9): p. 1589-97. doi:10.1200/JCO.2004.08.163

    Article  CAS  PubMed  Google Scholar 

  54. Weiss G, Langer C, Rosell R: Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol, 2006. 24(27): p. 4405-11. doi:10.1200/JCO.2006.06.7835

    Article  CAS  PubMed  Google Scholar 

  55. Frasci, G., etal., Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial. Lung Cancer, 2001. 34 Suppl 4: p. S65-9. doi:10.1016/S0169-5002(01)00392-0

    Article  PubMed  Google Scholar 

  56. Hainsworth JD, Spigel DR, Farley C: Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer, 2007. 110(9): p. 2027-34. doi:10.1002/cncr.23019

    Article  CAS  PubMed  Google Scholar 

  57. Bonomi P, Kim K, Fairclough D: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol, 2000. 18(3): p. 623-31.

    CAS  PubMed  Google Scholar 

  58. Langer CJ, Manola J, Bernardo P: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst, 2002. 94(3): p. 173-81.

    PubMed  Google Scholar 

  59. Schiller JH, Harrington D, Belani CP: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002. 346(2): p. 92-8. doi:10.1056/NEJMoa011954

    Article  CAS  PubMed  Google Scholar 

  60. Langer CJ, Vangel M, Schiller J, etal.: Age-specific subanalysis of ECOG 1594: Fit elderly patients (70–80 YRS) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol 2003, 22:abstr 2571

  61. Socinski MA, Schell MJ, Peterman A: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol, 2002. 20(5): p. 1335-43. doi:10.1200/JCO.20.5.1335

    Article  CAS  PubMed  Google Scholar 

  62. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA: The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer, 2003. 98(4): p. 779-88. doi:10.1002/cncr.11548

    Article  CAS  PubMed  Google Scholar 

  63. Belani CP, Ramalingam S, Perry MC: Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. J Clin Oncol, 2008. 26(3): p. 468-73. doi:10.1200/JCO.2007.13.1912

    Article  CAS  PubMed  Google Scholar 

  64. Ramalingam S, Perry MC, La Rocca RV: Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer, 2008. 113(3): p. 542-6. doi:10.1002/cncr.23583

    Article  CAS  PubMed  Google Scholar 

  65. Fossella F, Pereira JR, von Pawel J: Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol, 2003. 21(16): p. 3016-24. doi:10.1200/JCO.2003.12.046

    Article  CAS  PubMed  Google Scholar 

  66. Belani, C.P. and F. Fossella, Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer, 2005. 104(12): p. 2766-74. doi:10.1002/cncr.21495

    Article  CAS  PubMed  Google Scholar 

  67. Lilenbaum RC, Herndon JE, 2nd, List MA: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol, 2005. 23(1): p. 190-6. doi:10.1200/JCO.2005.07.172

    Article  CAS  PubMed  Google Scholar 

  68. Tsukada H, Yokoyama A, Nishiwaki Y, etal., Lung Cancer Study Group of the Japan Clinical Oncology Group (JCOG): Randomized controlled trial comparing docetaxel (D)-cisplatin (P) combination with D alone in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): JCOG0207. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 2007, 25(18S; June 20 Suppl):7629

  69. Gridelli C, Maione P, Illiano A: Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies. J Clin Oncol, 2007. 25(29): p. 4663-9. doi:10.1200/JCO.2007.12.5708

    Article  CAS  PubMed  Google Scholar 

  70. Shepherd FA, Rodrigues Pereira J, Ciuleanu T: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005. 353(2): p. 123-32. doi:10.1056/NEJMoa050753

    Article  CAS  PubMed  Google Scholar 

  71. Bezjak A, Tu D, Seymour L: Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR21. J Clin Oncol, 2006. 24(24): p. 3831-7. doi:10.1200/JCO.2006.05.8073

    Article  CAS  PubMed  Google Scholar 

  72. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA: Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR21. J Clin Oncol, 2008. 26(14): p. 2350-7. doi:10.1200/JCO.2007.15.2280

    Article  CAS  PubMed  Google Scholar 

  73. Jackman DM, Yeap BY, Lindeman NI: Phase II clinical trial of chemotherapy-naive patients >or =70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol, 2007. 25(7): p. 760-6. doi:10.1200/JCO.2006.07.5754

    Article  CAS  PubMed  Google Scholar 

  74. Crino L, Cappuzzo F, Zatloukal P: Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol, 2008. 26(26): p. 4253-60. doi:10.1200/JCO.2007.15.0672

    Article  CAS  PubMed  Google Scholar 

  75. Gridelli C, Maione P, Castaldo V, Rossi A: Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer, 2003. 89(10): p. 1827-9. doi:10.1038/sj.bjc.6601387

    Article  CAS  PubMed  Google Scholar 

  76. Hotta K, Ueoka H, Kiura K: Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Acta Oncol, 2005. 44(7): p. 717-22. doi:10.1080/02841860500256215

    Article  CAS  PubMed  Google Scholar 

  77. Thatcher N, Chang A, Parikh P: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005. 366(9496): p. 1527-37. doi:10.1016/S0140-6736(05)67625-8

    Article  CAS  PubMed  Google Scholar 

  78. Lynch TJ, Patel TD, Dreisbach L, etal.: Overall survival (os) results from the phase III trial BMS 099: Cetuximab  + Taxane/Carboplatin as 1st-line treatment for advanced NSCLC. Multidisciplinary Symposium in Thoracic Oncology, 2008, Chicago, IL

  79. Manegold C, von Pawel J, Zatloukal P, etal., the BO17704 Study Group: Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 2007, 25(18S; June 20 Suppl):LBA7514

  80. Ramalingam SS, Dahlberg SE, Langer CJ: Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol, 2008. 26(1): p. 60-5. doi:10.1200/JCO.2007.13.1144

    Article  CAS  PubMed  Google Scholar 

  81. Wakelee HA, Dahlberg SE, Brahmer JR, etal.: Increased benefit from Bevacizumab (BEV) in younger women with advanced NSCLC on Eastern Cooperate Oncology Group (ECOG) 4599. In ASTRO/IASLC, Chicago, IL 2008

  82. Merza T, Howard LM, Junagadhwalla M, Gajra A: Exclusions to use of bevacizumab in elderly veterans with advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 2007, 25(18S; June 20 Suppl):18046

  83. Hippocrates, Epidemics, bk. I, ch. 11. 460–377 B.C

  84. Rajeswaran A, Trojan A, Burnand B, Giannelli M: Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer, 2008.59(1): p.1-11. doi:10.1016/j.lungcan.2007.07.012

    Article  PubMed  Google Scholar 

  85. Strauss GM, Herndon JE, 2nd, Maddaus MA: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol, 2008. 26(31): p. 5043-51. doi:10.1200/JCO.2008.16.4855

    Article  CAS  PubMed  Google Scholar 

  86. Marinello R, Marenco D, Roglia D: Predictors of treatment failures during chemotherapy: A prospective study on 110 older cancer patients. Arch Gerontol Geriatr, 2008.

    Article  PubMed  Google Scholar 

  87. National Center for Health Statistics. Life Tables of the United States, 2004. http://www.cdc.gov/nchs/products/pubs/pubd/lftbls/life/1966.htm. Cited January 5, 2009

  88. Lee SJ, Lindquist K, Segal MR, Covinsky KE Development and validation of a prognostic index for 4-year mortality in older adults. JAMA, 2006. 295(7): p. 801-8. doi:10.1001/jama.295.7.801

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, University of Pennsylvania, 3400 Civic center Boulevard, PCAM 2, Philadelphia, PA, 19104, USA

    Jared Weiss MD & Corey Langer MD

Authors
  1. Jared Weiss MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Corey Langer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jared Weiss MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Weiss, J., Langer, C. NSCLC in the Elderly—The Legacy of Therapeutic Neglect. Curr. Treat. Options in Oncol. 10, 180–194 (2009). https://doi.org/10.1007/s11864-009-0099-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-009-0099-z

Keywords

Search

Navigation